Cargando…

Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

BACKGROUND: Ripretinib is a novel switch-control kinase inhibitor that inhibits KIT and PDGFRA signaling. In the INVICTUS phase 3 trial, ripretinib increased median progression-free survival and prolonged overall survival vs. placebo in ≥ fourth-line advanced GIST. Here, we report prespecified analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schöffski, Patrick, George, Suzanne, Heinrich, Michael C., Zalcberg, John R., Bauer, Sebastian, Gelderblom, Hans, Serrano, César, Jones, Robin L., Attia, Steven, D’Amato, Gina, Chi, Ping, Reichardt, Peter, Becker, Claus, Shi, Kelvin, Meade, Julie, Ruiz-Soto, Rodrigo, Blay, Jean-Yves, von Mehren, Margaret
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746146/ https://www.ncbi.nlm.nih.gov/pubmed/36514034 http://dx.doi.org/10.1186/s12885-022-10379-9

Ejemplares similares

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
por: Zalcberg, John R., et al.
Publicado: (2021)

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
por: Bauer, Sebastian, et al.
Publicado: (2022)

Ripretinib for the treatment of advanced gastrointestinal stromal tumor
por: Zalcberg, John R.
Publicado: (2021)

Invictus
Publicado: (2010)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Management of Patients With Advanced Gastrointestinal Stromal Tumor: Emphasis on Fourth-Line Treatment With Ripretinib
por: Brackert, Sandra, et al.
Publicado: (2023)

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib
por: Janku, Filip, et al.
Publicado: (2020)

Ripretinib for gastrointestinal stromal tumours
Publicado: (2021)

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward
por: Lostes-Bardaji, M. Julia, et al.
Publicado: (2021)

Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
por: Janku, F., et al.
Publicado: (2022)

Process evaluation of the Invictus Pathways Program
por: Post, Dannielle, et al.
Publicado: (2023)

Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Emerging Data on the Safety and Efficacy of Ripretinib for the Treatment of Gastrointestinal Stromal Tumors
por: Thirasastr, Prapassorn, et al.
Publicado: (2023)

Correction to: Ripretinib: First Approval
por: Dhillon, Sohita
Publicado: (2020)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study
por: Li, Jian, et al.
Publicado: (2022)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

A Longitudinal Examination of Military Veterans’ Invictus Games Stress Experiences
por: Roberts, Gareth A., et al.
Publicado: (2019)

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
por: Li, Xiaoyan, et al.
Publicado: (2022)

Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study
por: Yang, Weili, et al.
Publicado: (2023)

Militarizing politics of recognition through the Invictus Games: post-heroic exalting of the armed forces
por: West, Brad
Publicado: (2022)

A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor
por: Pantaleo, Maria A., et al.
Publicado: (2022)

DOACs in Valvular Heart Disease: Latest Key Updates on PROACT Xa (Apixaban) and INVICTUS (Rivaroxaban)
por: Ryu, Rachel
Publicado: (2022)

Genotyping guided ripretinib directly after the progression of first-line imatinib therapy in advanced gastrointestinal stromal tumor: a case report
por: Huang, Shaoqing, et al.
Publicado: (2022)

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial
por: Reichardt, Peter, et al.
Publicado: (2016)

INVICTUS: Vitamin K antagonists remain the standard of care for rheumatic heart disease-associated atrial fibrillation
por: Kotit, Susy
Publicado: (2023)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Multi-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Isolation and Annotation of the Genome Sequences of Bacteriophages InvictusManeo (Subcluster K5) and Netyap (Subcluster L2)
por: Flota, Maximiliano F., et al.
Publicado: (2022)

The physical, psychological, and social impacts of participation in the Invictus Pathways Program: A qualitative analysis of veterans’ perceptions and experiences
por: Post, Dannielle, et al.
Publicado: (2023)

Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: two case reports and literature review
por: Zhang, Yefan, et al.
Publicado: (2023)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique
por: Wang, Hui-jun, et al.
Publicado: (2021)

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
por: Wagner, A. J., et al.
Publicado: (2017)

The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique [Corrigendum]
Publicado: (2023)

Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy
por: George, Suzanne, et al.
Publicado: (2021)

Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial
por: Jones, Robin L., et al.
Publicado: (2021)

Large-Scale, Multicenter, Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China
por: Zhang, Xinhua, et al.
Publicado: (2023)

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
por: Blay, J.-Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aq1m5ldghn4e5e586kdfoi6nj4